Pemphigus vulgaris (PV) is an autoimmune disease characterized by blistering sores on skin and mucosal membranes, caused by autoantibodies primarily targeting the cellular adhesion protein, desmoglein-3 (Dsg3). To better understand how Dsg3-specific autoantibodies develop and cause disease in humans, we performed a cross-sectional study of PV patients before and after treatment to track relevant cellular responses underlying disease pathogenesis, and we provide an in-depth analysis of two patients by generating a panel of mAbs from single Dsg3-specific memory B cells (MBCs). Additionally, we analyzed a paired sample from one patient collected 15-months prior to disease diagnosis. We find that Dsg3-specific MBCs have an activated phenotype and show signs of ongoing affinity maturation and clonal selection. Monoclonal antibodies (mAbs) with pathogenic activity primarily target epitopes in the extracellular domains EC1 and EC2 of Dsg3, though they can also bind to the EC4 domain. Combining antibodies targeting different epitopes synergistically enhances in vitro pathogenicity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684256PMC
http://dx.doi.org/10.1016/j.celrep.2019.06.066DOI Listing

Publication Analysis

Top Keywords

ongoing affinity
8
affinity maturation
8
pemphigus vulgaris
8
vulgaris autoimmune
8
autoimmune disease
8
disease
5
single-cell analysis
4
analysis suggests
4
suggests ongoing
4
maturation drives
4

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, USA.

Background: The spread of tau in Alzheimer's Disease (AD) can be tracked in vivo using [F-18]MK6240, a PET radioligand that binds to tau aggregates in AD with high affinity. However, significant MK6240 signal is also observed in the meninges and sinus and the extra cerebral binding (ECB) signal from these regions can spill into exterior brain regions complicating evaluation of early stage AD tauopathy. This study evaluates the magnitude and variability of ECB in a large imaging cohort to identify trends in this signal.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Purdue, West Lafayette, IN, USA.

Background: Alzheimer's disease (AD) is a highly complex neurological disorder, with Late-Onset AD (LOAD) being its most common form. INPP5D has been identified as a risk gene for AD and is involved in the TREM2 signaling pathway, which is crucial for microglial activity. INPP5D encodes SHIP1, a protein phosphatase that disrupts TREM2 signaling by converting PIP3 into PIP2, thereby inhibiting the PI3K-mediated activation of Akt-dependent signaling, which is essential for the clearance of amyloid oligomers, fibrils, and plaques.

View Article and Find Full Text PDF

Background: The spread of tau in Alzheimer's Disease (AD) can be tracked in vivo using [F-18]MK6240, a PET radioligand that binds to tau aggregates in AD with high affinity. However, significant MK6240 signal is also observed in the meninges and sinus and the extra cerebral binding (ECB) signal from these regions can spill into exterior brain regions complicating evaluation of early stage AD tauopathy. This study evaluates the magnitude and variability of ECB in a large imaging cohort to identify trends in this signal.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

MRC Protein Phosphorylation and Ubiquitylation Unit, Dundee, Scotland, United Kingdom.

Background: Accumulation of misfolded a-synuclein protein in intracellular inclusion bodies of dopaminergic neurons underlies the pathogenesis of synucleinopathies, which include Parkinson's Disease (PD), Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA). Therefore, clearance of misfolded α-synuclein from dopaminergic neurons could in principle offer a an approach for modifying synucleinopathies, which currently remain untreatable.

Method: In this study, we employ the Affinity-directed PROtein Missile (AdPROM) system consisting of the substrate receptor of the CUL2-E3 ligase complex VHL and a nanobody selectively recognising the human α-synuclein protein RESULT: We demonstrate targeted degradation of endogenous α-synuclein from human cell lines with exquisite selectivity.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Eisai Inc., Nutley, NJ, USA.

Alzheimer's disease pathophysiology is believed to involve various abnormalities, including those of amyloid beta (Ab) peptide and tau processing, inflammation, oxidative stress, and vascular risk factors. Aβ peptides exist in a dynamic continuum of conformational states from monomeric Aβ, to soluble progressively larger Aβ assemblies that include a range of low molecular weight oligomers to higher molecular weight protofibrils, and finally to insoluble fibrils (plaques). Various lines of evidence support the "amyloid hypothesis" that Aβ plays a central role in the pathogenesis of AD, and several immunotherapies have been developed to interact with this cascade in various different places which may reduce the number of soluble aggregates and insoluble Aβ fibrils deposited in the brain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!